[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 66 of about 66
1. Kuttikat A, Keat A, Hughes R, Hakim A, Chakravarty K: A case of polymyalgia rheumatica, microscopic polyangiitis, and B-cell lymphoma. Nat Clin Pract Rheumatol; 2006 Dec;2(12):686-90; quiz 1p following 691
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 73-year-old, previously well woman was admitted to an emergency department because of a 3-month history of severe proximal girdle pain and stiffness with loss of appetite and weight.
  • At the time of development of jaundice, biochemical and hematological screening, CT of the abdomen and ultrasound-guided biopsy of a pancreatic mass were conducted.
  • DIAGNOSIS: Polymyalgia rheumatica, antineutrophil-cytoplasmic-antibody-positive microscopic polyangiitis with renal involvement and B-cell lymphoma of the head of the pancreas.
  • For B-cell lymphoma of the head of the pancreas, the patient received cyclophosphamide, doxorubicin, vincristine and prednisolone once monthly.
  • [MeSH-minor] Aged. Alendronate / therapeutic use. Antibodies, Antineutrophil Cytoplasmic / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antirheumatic Agents / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Female. Humans. Immunosuppressive Agents / therapeutic use. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Microscopic polyangiitis.
  • MedlinePlus Health Information. consumer health - Polymyalgia Rheumatica.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17133254.001).
  • [ISSN] 1745-8382
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; X1J18R4W8P / Alendronate
  •  go-up   go-down


2. Dumonceau JM, Vonlaufen A: Pancreatic endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy; 2007 Feb;39(2):124-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endoscopic retrograde cholangiopancreatography (ERCP).
  • We review developments in five areas of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) and management of pancreatic tumors during the period September 2005-August 2006.
  • First, in the management of painful chronic pancreatitis, the use of multiple plastic stents for aggressive dilation of strictures located in the head of the pancreas has been put forward to resolve two significant issues associated with current techniques, i. e., the requirement for numerous ERCPs for stent exchange and the high relapse rate after stent removal.
  • We then discuss the identification of protective factors against post-ERCP pancreatitis following pancreatic sphincterotomy.
  • Next, bearing in mind the prospect of increasing use of neoadjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma, new evidence supporting the systematic use of self-expandable metal biliary stents before cancer staging is presented and critically considered.
  • Finally two centers with a high volume of cases have reported their experience with the drainage of pancreatic fluid collections with or without endosonography (EUS) guidance.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Pancreatitis / therapy. Stents
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chronic Disease. Drainage / methods. Humans. Pancreatic Ducts / pathology. Risk Factors. Sphincterotomy, Endoscopic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327971.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 23
  •  go-up   go-down


3. Glaser M, Roskar Z, Skalicky M, Krajnc I: Cystic dystrophy of the duodenal wall in a heterotopic pancreas. Wien Klin Wochenschr; 2002 Dec 30;114(23-24):1013-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic dystrophy of the duodenal wall in a heterotopic pancreas.
  • Cystic dystrophy of the duodenal wall in heterotopic pancreas is a rare disease affecting younger men in particular.
  • On account of its difficult diagnosis and nonspecific signs, it was first described in 1970.
  • A 51-year-old male patient was admitted for clarification of several months of severe pain in the upper abdomen accompanied by weight-loss, and due to ultrasonically established suspicion of carcinoma in the head of the pancreas.
  • Ultrasound examination showed cystic changes in the duodenal wall and in the vicinity of the head of the pancreas.
  • Only with the aid of endoscopic ultrasound, could bizarre cystic changes in the submucosa of the duodenal wall be detected, which was also confirmed by computer tomography.
  • Cystic changes with fibrosis, pancreatic ducts and lobi without anatomic or vascular connection to the pancreas are found.
  • Prior to the introduction of imaging techniques such as endoscopic ultrasonography, computer tomography and nuclear magnetic resonance, the diagnosis could only be made by means of an operative procedure.
  • Treatment is primarily surgical; smaller cysts can be treated by endoscopic fenestration.
  • Pharmacological treatment with somatostatin is rarely performed.
  • [MeSH-major] Choristoma. Cysts. Duodenal Diseases. Pancreas
  • [MeSH-minor] Abdominal Pain / drug therapy. Abdominal Pain / etiology. Endoscopy. Hormones / administration & dosage. Hormones / therapeutic use. Humans. Injections, Subcutaneous. Male. Middle Aged. Somatostatin / administration & dosage. Somatostatin / therapeutic use. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635471.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Hormones; 51110-01-1 / Somatostatin
  •  go-up   go-down


Advertisement
4. Hopt UT: [Treatment of carcinoma of the pancreatic head]. Zentralbl Chir; 2006 Apr;131(2):115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of carcinoma of the pancreatic head].
  • [Transliterated title] Therapie des Pankreaskopfkarzinoms.
  • For patients with carcinoma in the head of the pancreas surgical resection remains the only chance of cure.
  • Only a small percentage of all patients suffering from pancreas carcinoma are good candidates for an operative therapy.
  • The most frequent contraindications are metastases in the liver or the peritoneum or a locally too advanced tumor.
  • The extent of surgical resection necessary in patients with pancreas carcinoma is still in discussion.
  • A substantial improvement of long term- survival can only be expected from new multimodal therapeutic strategies.
  • Adjuvant chemotherapy should strongly be recommended after resection of a pancreas carcinoma.
  • Neoadjuvant therapy on the other hand is still an experimental procedure and under evaluation in ongoing prospective randomized studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Humans. Lymph Node Excision / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612777.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Matsuda M, Watanabe G, Mine S, Hashimoto M: [Fatal liver failure associated with gemcitabine hydrochloride therapy]. Gan To Kagaku Ryoho; 2008 Jan;35(1):157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal liver failure associated with gemcitabine hydrochloride therapy].
  • We report a case of fatal liver failure associated with gemcitabine hydrochloride(GEM)therapy.
  • In February 2005, a 79-year-old man with a history of diabetes mellitus and chronic hepatitis C was admitted for the treatment of carcinoma of the head of the pancreas.
  • Abdominal CT revealed no distant metastases, but the tumor had invaded the portal vein.
  • Surgery was too risky because of his age and condition, so radiation therapy(60 Gy)was combined with GEM(800 mg on days 1 and 8 of a 3-week cycle).
  • The treatment was well tolerated.
  • Autopsy revealed extensive centrilobular necrosis of the liver and confirmed a diagnosis of drug-induced liver failure.
  • Careful monitoring is necessary during GEM therapy, especially in patients with liver dysfunction.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Liver Failure / chemically induced. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Male. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Koizumi M, Sata N, Shimura K, Tsukahara M, Yoshizawa K, Kurihara K, Hyodo M, Yasuda Y, Nagai H: [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
  • A 76-year-old man developed jaundice and was hospitalized in January 2002.
  • A 3 cm tumor was found in the head of the pancreas by abdominal CT, and the patient underwent laparotomy.
  • The tumor was histologically diagnosed as a well-differentiated adenocarcinoma, and showed extensive invasion to the portal vein (T4NXM 0 Stage IV a).
  • On the basis of a drug sensitivity test, chemotherapy with 800 mg/m2/week gemcitabine was administered.
  • The patient showed prolonged NC without any symptoms for 22 months, although the CEA and DUPAN-2 levels gradually increased during this time and massive ascites were detected in a routine abdominal CT at 22 months postsurgery.
  • The patient died after 25 months of chemotherapy.
  • Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Screening Assays, Antitumor. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Pandya G, Dixit R, Shelat V, Dixit K, Shah N, Shah K: Obstructive jaundice: a manifestation of pancreatic tuberculosis. J Indian Med Assoc; 2007 Mar;105(3):133-4, 136
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice: a manifestation of pancreatic tuberculosis.
  • Tuberculosis of the pancreas is extremely rare and is most often associated with miliary tuberculosis or occurs in the immunocompromised patients.
  • A case of isolated pancreatic tuberculosis in an immunocompetent patient is presented with constitutional symptoms and obstructive jaundice.
  • Ultrasonography and computerised tomography showed a mass lesion in the head of pancreas.
  • Histological examination of the peripancreatic lymph node and fine needle aspiration cytology from the head of pancreas confirmed the diagnosis following laparotomy.
  • Patient recovered following the administration of antituberculosis chemotherapy.
  • [MeSH-major] Antitubercular Agents / administration & dosage. Jaundice, Obstructive / etiology. Pancreatic Diseases / complications. Tuberculosis / complications
  • [MeSH-minor] Adult. Diagnostic Imaging. Drug Therapy, Combination. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824465.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


8. Barreda Bolaños F, Landeo Aliaga I, Pando Huarcaya S, Bayro Peñaloza F: [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography]. Rev Gastroenterol Peru; 2008 Apr-Jun;28(2):162-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography].
  • [Transliterated title] Adenocarcinoma de páncreas en paciente joven diagnosticado por ultrasonografía endoscópica.
  • The Pancreatic adenocarcinoma appears generally in patients with more than 60 years old.
  • We report the case of a man of 29 years diagnosed and treated in the National Institute of Neoplastic Diseases (INEN), that presented symptoms as: dorsalgia, jaundice and weight loss.
  • The tomografic image showed a mass located in the head of the pancreas with hepatic and ganglionar metastases.
  • It was evaluated by means of endoscopic ultrasonography (USE) and performed a directed fine needle puncture aspiration (PAAF), that obtained a bad differentiated adenocarcinoma from the pancreas.
  • An endoscopic biliary drainage by PCRE was realized later and treatment with chemotherapy started.
  • We present the case by the unusual occurrence in the related age group and by the importance of the puncture guided by endoscopic ultrasonography in the diagnosis and handling of this pathology [corrected]
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):293
  • (PMID = 18641779.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


9. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • Specific information regarding intraductal papillary mucinous neoplasm (IPMN) recurrence is limited because most series are small and the follow-up interval is short.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • The patient did not receive postoperative chemotherapy and was monitored with transaxial imaging at regular intervals.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Saif MW: Pancreatoblastoma. JOP; 2007;8(1):55-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatoblastoma (PB), or infantile pancreatic carcinoma, is an extremely rare pancreatic tumor in childhood, comprising 0.5% of pancreatic non-endocrine tumors.
  • Mechanical obstruction of the upper duodenum and gastric outlet by tumor in the head of the pancreas may be associated with vomiting, jaundice and gastrointestinal bleeding.
  • The majority of these tumors arise in the head of the pancreas.
  • Ultrasound and CT scan may be useful but preoperative diagnosis is often quite difficult.
  • The treatment of choice is complete resection, that may often be curative.
  • The role of adjuvant chemotherapy or radiotherapy is still under discussion due to small number of patients treated as yet.
  • Chemotherapy regimens consisting of cyclophosphamide, etoposide, doxorubicin, and cisplatin have been used in neoadjuvant setting with anecdotal benefit.
  • Prognosis of this rare tumor is good, when resected completely.
  • On the whole, PB is regarded to be a curable tumor; hence the clinical diagnosis should be made early.
  • Awareness of this rare tumor of pancreas is essential for early detection and proper management.
  • The author review the clinical presentation, etiology, diagnosis, treatment and prognosis of PB in this presentation.
  • [MeSH-major] Carcinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Pancreas / pathology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228135.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Onoue S, Katoh T, Chigira H, Shibata Y, Matsuo K, Suzuki M: Carcinoma of the head of the pancreas. Hepatogastroenterology; 2002 Mar-Apr;49(44):549-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the head of the pancreas.
  • BACKGROUND/AIMS: Extended radical surgery might provide a survival advantage for patients with carcinoma of the head of the pancreas.
  • METHODOLOGY: Between January 1980 and December 1999, 144 patients with carcinoma of the head of the pancreas were treated in a community hospital setting, of whom 69 patients who underwent radical surgery were retrospectively reviewed.
  • No patients received adjuvant chemotherapy or radiotherapy.
  • RESULTS: The surgical resection rate was 47.9% with a surgical mortality rate of 4.3% during this period.
  • The overall 5-year survival rate after radical surgery was 16.1% with a median survival of 12 months.
  • Long-term survivors had less than two positive lymph nodes in the posterior pancreatic head.
  • CONCLUSIONS: Extended radical surgery did not prolong survival for patients with carcinoma of the head of the pancreas.
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11995493.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic Cancer Registry in Japan: 20 years of experience.
  • The prognosis of pancreatic cancer is defined by the histology and extent of disease.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • The overall resectability rate of pancreatic cancer is 40% in Japan.
  • Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis


13. Tanaka H, Takamori H, Eto S, Ozaki N, Akaboshi S, Nakahara O, Ida S, Furuhashi S, Abe S, Horino K, Beppu T, Baba H: [Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1783-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer].
  • Imagings revealed cancer of the head of the pancreas.
  • We performed pancreaticoduodenectomy for pancreatic cancer.
  • The histopathological diagnosis was tubular adenocarcinoma of the pancreas.
  • As a postoperative adjuvant chemotherapy, gemcitabine hydrochloride (GEM) was injected at a dose of 800mg/m2 once a week.
  • With these conservative treatments, she recovered completely.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Hepatic Encephalopathy / chemically induced. Hepatitis B / complications. Liver / injuries. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Amino Acids, Branched-Chain / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lactulose / therapeutic use. Tomography, X-Ray Computed


14. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones L, Wyld P, Gillams A, Hatfield AW: Photodynamic therapy for cancer of the pancreas. Gut; 2002 Apr;50(4):549-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for cancer of the pancreas.
  • BACKGROUND: Few pancreatic cancers are suitable for surgery and few respond to chemoradiation.
  • Photodynamic therapy produces local necrosis of tissue with light after prior administration of a photosensitising agent, and in experimental studies can be tolerated by the pancreas and surrounding normal tissue.
  • AIMS: To undertake a phase I study of photodynamic therapy for cancer of the pancreas.
  • PATIENTS: Sixteen patients with inoperable adenocarcinomas (2.5-6 cm in diameter) localised to the region of the head of the pancreas were studied.
  • All presented with obstructive jaundice which was relieved by biliary stenting prior to further treatment.
  • Three days later, light was delivered to the cancer percutaneously using fibres positioned under computerised tomographic guidance.
  • Three had subsequent chemotherapy.
  • RESULTS: All patients had substantial tumour necrosis on scans after treatment.
  • Eleven had a Karnofsky performance status of 100 prior to treatment.
  • Two patients with tumour involving the gastroduodenal artery had significant gastrointestinal bleeds (controlled without surgery).
  • Three patients developed duodenal obstruction during follow up that may have been related to treatment.
  • There was no treatment related mortality.
  • The median survival time after photodynamic therapy was 9.5 months (range 4-30).
  • Seven of 16 patients (44%) were alive one year after photodynamic therapy.
  • CONCLUSIONS: Photodynamic therapy can produce necrosis in pancreatic cancers with an acceptable morbidity although care is required for tumours invading the duodenal wall or involving the gastroduodenal artery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. Photochemotherapy / methods
  • [MeSH-minor] Aged. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1988 May;38(1):4-9 [2967404.001]
  • [Cites] Photochem Photobiol. 1987 Nov;46(5):795-800 [3441502.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):1-12 [2121925.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1108-15 [1764374.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):786-90 [1393474.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):248-54 [8054272.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1185-9 [7953356.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):337-44 [7835574.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Laryngoscope. 1995 Aug;105(8 Pt 1):867-71 [7630302.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1473-9 [8664115.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Cancer. 1997;76(6):713-8 [9310235.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1370-6 [9361591.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):1-7 [9468416.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Gut. 1998 Sep;43(3):345-9 [9863479.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] BJU Int. 1999 Nov;84(7):821-6 [10532979.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):17-31 [10638554.001]
  • [Cites] J Natl Cancer Inst. 1988 Jul 20;80(10):751-5 [2898536.001]
  • (PMID = 11889078.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1773165
  •  go-up   go-down


15. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


16. Fujii M, Sato H, Ogasawara T, Ando T, Tsujii S, Nagahori J, Komatsu Y, Matsuoka A: [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1987-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy].
  • A 55-year-old man underwent a pylorus-preserving pancreatoduodenectomy in August 2006 because of acinar cell carcinoma of the head of the pancreas.
  • Since abdominal CT revealed multiple liver metastases, we started systemic chemotherapy with gemcitabine (1,400 mg/body, day 1, 8, 15/q4w) in October 2006.
  • At the beginning of this treatment, it seemed to be a stable disease, but CT revealed tumor progression in January 2007.
  • Despite the change to oral chemotherapy with S-1 (100 mg/body, day 1-14/q3w), tumors were markedly enlarged in March 2007.
  • Therefore, we selected combination chemotherapy with oral S-1 and hepatic arterial infusion of CDDP (50 mg/body) as third-line.
  • After 6 months of treatment, abdominal CT revealed marked shrinkage of tumors, accompanied by a decrease in AFP level.
  • Though the patient died of hepatic failure in July 2009 (33 months after recurrence), he spent most of his time at home and worked as usual.
  • We suggest that combination chemotherapy with oral S-1 and intra-arterial CDDP can be effective treatments for pancreatic acinar cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Fatal Outcome. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Takeyama O, Usui Y: [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases]. Gan To Kagaku Ryoho; 2005 Feb;32(2):247-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
  • Abdominal CT scan and ultrasonography both revealed a tumor in the head of the pancreas.
  • The patient was diagnosed as having advanced pancreatic cancer with multiple lung metastases.
  • The primary tumor showed a partial response to the administration of gemcitabine 1,000 mg/m2 on days 1, 8 and 15 of a 28-day cycle.
  • Concurrent treatment with 5-fluorouracil (200 mg/day) was efficacious against the lung metastases.
  • One year later the pancreatic and lung tumors had enlarged, and cisplatin (20 mg/body) was added to the protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Quality of Life. Survivors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Adham M, Mirza DF, Chapuis F, Mayer AD, Bramhall SR, Coldham C, Baulieux J, Buckels J: Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors. HPB (Oxford); 2006;8(6):465-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From 1989 to 2002, 45 patients (21 men, 24 women) underwent pancreatectomy for a pancreatic mass: Whipple's procedure (n=33), total pancreatectomy (n=10) or left splenopancreatectomy (n=2), along with a vascular resection, i.e. venous (n=39), arterial (n=1) or venous + arterial (n=5).
  • Reoperations were performed for portal vein thrombosis (n=1), pancreatic leak (n=1), gastric outlet syndrome (n=1) and gastrointestinal bleeding (n=1).
  • In all, 43 patients had cancer on pathology examination, with retropancreatic invasion in 72% and lymph node extension in 62.8%.
  • A multivariate analysis of prognostic variables identified tumour location (other than head of pancreas), neoadjuvant chemotherapy and advanced disease stage as adverse factors for DFS.
  • Tumour localization, tumour stage, neoadjuvant treatment and tumour recurrence are explanatory variables of survival.
  • Tumour localization, tumour stage and neoadjuvant treatment were explanatory variables for DFS.
  • However, the type and extent of vascular resections as well as vessel wall invasion does not affect survival and DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):188-99 [1727753.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] N Y State J Med. 1971 Feb 1;71(3):366-8 [4323555.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1596-600 [16201124.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1056-61 [16006800.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):130-4 [15730937.001]
  • [Cites] Ann Surg. 1992 Mar;215(3):231-6 [1543394.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):110-3 [15004752.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):263-6 [12630036.001]
  • [Cites] Surg Today. 2002;32(7):598-601 [12111516.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):258-62 [11941970.001]
  • [Cites] J Am Coll Surg. 2001 Nov;193(5):576-8 [11708518.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2609-15 [11569683.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):492-7 [10228849.001]
  • [Cites] Surg Today. 1999;29(1):16-22 [9934826.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] AJR Am J Roentgenol. 1997 Apr;168(4):971-7 [9124153.001]
  • [Cites] J Surg Res. 1996 Jul 15;64(1):32-4 [8806470.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):202-6 [8661548.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Jpn J Surg. 1983 Sep;13(5):385-94 [6366309.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1642-6 [7827892.001]
  • (PMID = 18333103.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020757
  •  go-up   go-down


19. Hackert T, Büchler MW, Werner J: Surgical options in the management of pancreatic cancer. Minerva Chir; 2009 Oct;64(5):465-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical options in the management of pancreatic cancer.
  • Management of pancreatic cancer is an interdisciplinary challenge as this tumor entity is still characterized by a poor prognosis and an overall long-term survival of only 1-5%.
  • From the oncological dimension, pancreatic cancer represents the fourth leading cause of cancer related mortality in the Western world with more than 100000 deaths in Europe and the USA per year.
  • A major problem is the early detection since 80-90% of pancreatic cancers are locally or systemically advanced at the time of diagnosis.
  • Yet, surgical therapy has to be embedded in an oncological concept of adjuvant treatment as postoperative chemotherapy is a key factor to further improve patient survival.
  • Numerous ongoing studies on new therapeutic agents like antibodies, antimetabolites and supportive agents reflect the current scientific and clinical struggle to achieve better outcome of pancreatic cancer patients in the future on the basis of initial tumor resection or if this is not possible as a palliative treatment.
  • Standard resections include partial pancreatico-duodenectomy with distal gastric resection or recently accepted as the preferable procedure preservation of the pylorus for tumors in the head of the pancreas, distal pancreatectomy for tumors of the corpus and tail as well as total pancreatectomy for more extended tumors or intraductal papillary mucinous neoplasias if necessary.
  • Today, standardization of surgical procedures and centralization of pancreatic surgery in high volume institutions guarantees best patient care and mortality rates below 5%.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Pancreaticoduodenectomy. Postoperative Complications / etiology. Postoperative Complications / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859037.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E: Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. J Surg Oncol; 2001 Apr;76(4):289-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature.
  • BACKGROUND: Solid-pseudopapillary tumor of the pancreas (SPT) is an exceptionally rare neoplasm in children.
  • It is of low malignant potential and occurs most frequently in young females.
  • PATIENTS AND METHODS: A cumulative review of the tumor's clinicopathological characteristics from the world's literature is presented.
  • Two tumors were located in the tail, one in the body and tail and one in the head of the pancreas (diameter: 7--15 cm).
  • Surgical procedures included three distal pancreatectomies and one partial duodenopancreatectomy (Whipple procedure).
  • Chemotherapy was initiated for this patient.
  • CONCLUSIONS: SPT is a rare differential diagnosis of a pancreatic mass in children.
  • It is mandatory to establish this diagnosis since complete surgical removal of the tumor even in case of metastases or local invasion offers an excellent prognosis.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11320522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


21. Snajdauf J, Rygl M, Petru O, Kalousova J, Kuklova P, Mixa V, Keil R, Hribal Z: Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children. Eur J Pediatr Surg; 2009 Dec;19(6):354-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children.
  • AIM OF STUDY: Aim of the study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors of the head of the pancreas.
  • METHODS: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results.
  • In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved.
  • Patients with body and tail involvement underwent distal pancreatic resection.
  • In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed.
  • She developed a biliary fistula which closed after three weeks with endoscopic stenting.
  • One patient with head resection developed a biliary fistula which closed after two weeks of stenting.
  • One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively.
  • All patients are alive without tumor recurrence at 6 months to 16 years after operation.
  • CONCLUSION: SPTP is a rare pancreatic tumor with a low degree of malignancy.
  • No perioperative chemotherapy is necessary.
  • Therefore duodenal resection in cases of SPTP in the head of the gland seems too invasive and mutilating.
  • The authors consider the duodenum-sparing technique to be more appropriate for the developing organism of a child.
  • [MeSH-major] Biliary Fistula / etiology. Carcinoma, Papillary / surgery. Duodenum. Pancreatectomy / adverse effects. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19821226.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, Gibbs JF: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol; 2002 Nov;9(9):855-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.
  • BACKGROUND: Neuroendocrine tumors of the pancreas are rare tumors.
  • METHODS: Fifty patients with a diagnosis of neuroendocrine tumors of the pancreas were retrospectively evaluated.
  • The following factors were evaluated for disease-specific mortality: age, sex, primary tumor location, functional status, type of primary tumor treatment, presence or absence of liver metastases, timing of liver metastases occurrence, and type of liver metastases treatment.
  • Aggressive treatment of the liver metastases included surgery, chemoembolization, or intrahepatic arterial infusion chemotherapy.
  • RESULTS: Twenty-three patients (47%) had tumor located in the head of the pancreas, and 29 patients (58%) had nonfunctioning tumor.
  • Factors that had a significant favorable effect on survival included curative resection of the primary tumor, metachronous liver metastases, absence of liver metastases, and aggressive treatment of the liver metastases.
  • CONCLUSIONS: Definitive surgical resection of the primary tumor, absence of liver metastases, metachronous liver metastases, and aggressive treatment of the liver metastases were predictors of long-term survival in patients with neuroendocrine tumors of the pancreas.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12417506.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kuramitsu T, Naganuma T, Zeniya A, Otani S, Yoshida T, Ito S, Matsudaira N, Kano M, Komatsu M: Poorly vascularized malignant insulinoma displaced the pancreatic ducts around the mass on endoscopic retrograde cholangiopancreatography. Intern Med; 2001 Jan;40(1):28-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly vascularized malignant insulinoma displaced the pancreatic ducts around the mass on endoscopic retrograde cholangiopancreatography.
  • Abdominal ultrasonography (US) and endoscopic US revealed an isoechoic mass measuring 25 mm in the head of the pancreas.
  • Endoscopic retrograde cholangiopancreatography (ERCP) revealed that the main pancreatic duct and its branches were displaced around the mass in the head of the pancreas.
  • On arteriography, a poorly vascularized tumor was observed.
  • Dynamic contrast-enhanced computed tomography (CT) showed a low-attenuation mass in the head of the pancreas.
  • Microscopically, the diagnosis was malignant insulinoma.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Female. Glucose / therapeutic use. Humans. Hyperinsulinism / etiology. Hypoglycemia / drug therapy. Hypoglycemia / etiology. Insulin / analysis. Magnetic Resonance Imaging. Mesenteric Arteries / radiography. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Unconsciousness / drug therapy. Unconsciousness / etiology

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201365.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Insulin; IY9XDZ35W2 / Glucose
  •  go-up   go-down


24. Kodjikian L, Grange JD, Rivoire M: Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):622-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
  • BACKGROUND: To report the protracted 9-year survival of a patient after surgical management of multiple liver metastases from uveal melanoma.
  • METHODS: A 30-year-old patient, treated for choroidal melanoma by proton beam therapy, was semiannually followed by abdominal ultrasonography.
  • Two years after initial treatment, a total body computed tomography scan suggested the diagnosis of isolated liver metastases.
  • RESULTS: Multiple wedge resections and postoperative intra-arterial chemotherapy with fotemustine were performed.
  • After 4 years, a metastatic nodule in the head of the pancreas was detected and surgically removed.
  • The patient finally died of carcinomatous meningitis 9 years of first treatment of metastases.
  • CONCLUSIONS: In the present case, the surgical control of liver metastases associated with intra-arterial chemotherapy prolonged the quality and length of life with progressive disease extension to other organs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatectomy / methods. Liver Neoplasms / mortality. Melanoma / mortality. Uveal Neoplasms / mortality
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Fatal Outcome. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Neoplasm Metastasis. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):127-30 [9591028.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S27-30 [9849406.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):122-9 [14692032.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Arch Ophthalmol. 1984 Jan;102(1):80-2 [6200095.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2219-23 [7848381.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):207-8; author reply 208 [15222009.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1561-8 [11013372.001]
  • [Cites] Am J Ophthalmol. 1998 Mar;125(3):407-9 [9512169.001]
  • (PMID = 15650857.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 7GR28W0FJI / Dacarbazine; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


25. Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, Oka M, Kinoshita H, Kimura W, Shimada H, Tanaka M, Nakao A, Hirata K, Yasuda H: The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg; 2009;16(4):485-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
  • BACKGROUND: Pancreatic carcinoma causes more than 20,000 deaths every year in Japan.
  • The role of (neo-) adjuvant chemotherapy for pancreatic carcinoma is still controversial.
  • METHODS: At the 34th Annual Meeting of the Japanese Society of Pancreatic Surgery in 2007, questionnaires were distributed regarding the use of (neo-) adjuvant chemo(radio)therapy for pancreatic carcinoma between 2001 and 2005.
  • There were a total of 1,846 cases of resected pancreatic carcinoma between 2001 and 2005.
  • The lesion was located in the head of the pancreas in 1,204 cases (71.7%), in the body in 353 cases (21.0%), and in the tail in 111 cases (6.6%).
  • Adjuvant chemotherapy (usually involving gemcitabine) was used in 66.0% of cases.
  • The use of adjuvant chemotherapy was found to improve the overall survival rate.
  • Interestingly, adjuvant chemotherapy only improved survival in late-stage (UICC stages IIB, III, and IV) but not early stage (IA, IB, and IIA) patients.
  • Survival was treatment duration-dependent, with patients who received more than 12 months of therapy having a 3-year survival rate of 51.2%.
  • CONCLUSION: This high volume retrospective data indicated the promising effect of gemcitabine-based adjuvant chemotherapy and the rational duration of adjuvant chemotherapy should be determined in the future prospective studies.
  • [MeSH-major] Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Health Surveys. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333537.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Tanigawa T, Hasuike Y, Yamada M, Fujiwara S, Murata H: [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2085-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy].
  • Computed tomography (CT) showed a mass in the head of the pancreas and a dilated bile duct.
  • As adjuvant chemotherapy, the patient received a hepatic arterial infusion with 5-FU to prevent liver metastasis.
  • A catheter was placed in the right femoral artery and intra-arterial chemotherapy was carried out for one week.
  • After the completion of chemotherapy, swelling and redness of the right inguinal region was observed.
  • Despite intravenous antibiotic therapy for 2 days, bleeding and pus discharge at the catheter root were observed.
  • In such cases, it is advisable to drain the infected pseudo-aneurysm following a prompt diagnosis, and perform a secondary bypass operation.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Male. Middle Aged. Pancreatic Neoplasms / therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037331.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • A resected case of gastric cancer is described.
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • Radical resection was not indicated, and we administered the following combination chemotherapy with TS-1 and CDDP.
  • 120 mg/day of TS-1 was orally administered for 3 weeks followed by 2 drug-free weeks as 1 course and 9 5 mg (60 mg/m(2)) of CDDP was administered intravenously on day 8.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology; 2006;6(4):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
  • The first discovery of a cerebellar metastasis of pancreatic carcinoma in a living patient is described.
  • Two years earlier the patient had undergone a pancreaticoduodenectomy for an adenocarcinoma of the head of the pancreas with a lymph node metastasis.
  • After complete surgical removal of the tumor, he underwent adjuvant chemoradiation.
  • Clinical evaluation revealed an intracranial tumor without signs of pancreatic recurrence.
  • The tumor was surgically removed.
  • One year later the patient developed multiple brain metastases and he is currently undergoing gemcitabine-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / radiography. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Male. Pancreaticoduodenectomy. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636605.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


29. Takagi T, Ueda N, Kanemoto H: [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)].
  • The patient was a 66-year-old female with Borrmann's type 4 gastric cancer complicated by metastasis to the liver and invasion of the head of the pancreas.
  • One course of chemotherapy was defined as 3 weeks of drug administration(TS-1 100 mg/body/day po for 21 days + CDDP 9 0 mg/body/day by iv drip on day 8), followed by a 2-week rest period.
  • Chemotherapy was started 13 days after the operation, and it was possible to continue it for 7 courses.
  • TS-1/CDDP therapy improved the patient's general condition.
  • The tumor marker levels were also decreased.
  • However, the efficacy of treatment began to decline,and ascites gradually developed during the fourth course of therapy.
  • The treatment regimen was then switched to TS-1 100 mg/body/day po for 14 days, followed by a 14-day rest period, combined with PTX 9 0 mg/body/day iv drip on day 1 and day 15, while the ascites was being controlled.
  • However, PTX was switched to CPT-11 because of gradual progression of peripheral neuropathy as a side effect of chemotherapy, and the patient subsequently died without any improvement in symptoms.
  • This report describes a case of advanced gastric cancer treated by combination chemotherapy with TS-1 as a key drug, which resulted in a long survival (1 year and 5 months)and improvement in quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pancreatic Neoplasms / pathology. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227747.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seminoma metastases mimicking primary pancreatic cancer.
  • BACKGROUND: A case of seminoma clinical stage III, arising from the right testis and mimicking a primary pancreatic malignancy is reported.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • A laparoscopic biopsy out of a suspicious lesion of the head of the pancreas and a surrounding lymph node was done.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • CONCLUSION: This case shows a seminoma with metastases at retroperitoneal site, mimicking a primary pancreatic neoplasm.
  • It provides an example of the possibility of an uncommon clinical appearance of seminoma metastases and again underlines the importance of exact radiological and histopathological examination to distinguish between curable and incurable tumor.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


31. Dang S, Atiq M, Saccente M, Olden KW, Aduli F: Isolated tuberculosis of the pancreas: a case report. JOP; 2009;10(1):64-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated tuberculosis of the pancreas: a case report.
  • CONTEXT: Pancreatic tuberculosis is a rare entity.
  • We hereby describe a case of pancreatic tuberculosis in an immunocompromized individual.
  • CASE REPORT: A fifty-year-old African-American gentleman with history of HIV non-compliant on anti-retroviral therapy presented with epigastric pain for five weeks duration.
  • CT scan of abdomen showed large necrotic node on the posterior aspect of the head of pancreas and multiple cystic masses adjacent to the pancreas.
  • Anti-tubercular therapy was initiated and resulted in gradual resolution of symptoms.
  • CONCLUSION: Pancreatic tuberculosis is rare and is frequently confused with pancreatic cancer on clinical presentation as well as on imaging studies.
  • Since it is a curable disease, accurate diagnosis is paramount CT or ultrasound guided biopsy is cornerstone of diagnosis.
  • Endoscopic ultrasound is now increasingly being used for obtaining tissue for diagnosis.
  • Anti-tubercular therapy is curative in majority of the cases.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Pancreatic Diseases / diagnosis. Tuberculosis / diagnosis
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. HIV-1. Humans. Male. Middle Aged. Mycobacterium tuberculosis / isolation & purification


32. Sváb J, Pesková M, Krusina L, Skrha J, Sindelka G: [Personal experience with surgical treatment of insulinoma]. Rozhl Chir; 2001 Feb;80(2):77-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Personal experience with surgical treatment of insulinoma].
  • In 42 a localized tumour was removed, in one diffuse adenomatosis was involved.
  • In three of the operated patients a malignant, enddocrinologically active insulinoma was confirmed.
  • Two patients were re-operated on account of a relapse.
  • For localization of the tumour before operation US, CT and angiographic examinations were used.
  • The tumour was found in the head of the pancreas in 13 patients (31%), in the body of the pancreas in 14 (33%) and in the tail of the pancreas in 15 (36%).
  • Surgery was successful in 82%, while the topographic preoperative examination aroused suspicion of a focus (i.e. insulinoma) only in 49% of the operated patients.
  • A total of 17 patients (8 after surgery and 9 without surgery) were successfully treated with diazoxide, in 9 patients this treatment is still administered.
  • Pharmacological treatment is therefore justified only in the first group of patients.
  • Our experience indicates that a surgical approach is suitable when the diagnosis is unequivocal, even when there is a negative topographic finding of imaging methods as in 33% of the operated patients the insulinoma was detected only on operation.
  • [MeSH-major] Insulinoma / surgery. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881920.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


33. Osti MF, Costa AM, Bianciardi F, De Nicolò M, Donato V, Silecchia G, Enrici RM: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori; 2001 Nov-Dec;87(6):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study.
  • AIMS AND BACKGROUND: To evaluate the efficacy of combined radiation therapy and continuous infusion of 5-fluorouracil in patients with locally advanced carcinoma of the pancreas.
  • METHODS: Between January 1992 and June 1999, 31 patients with locally advanced adenocarcinoma of the pancreas were treated in our Institute.
  • In 20 patients, the tumor (65%) was located in the head of the pancreas and in 11 (35%) in the body or tail; 13 cases also showed involved nodes.
  • Radiation therapy consisted in a median dose of 63 Gy in 33-36 fractions applied to the tumor and regional lymph nodes.
  • Chemotherapy with 5-fluorouracil in continuous infusion, 250 mg/m2 daily, was administered in the first and fifth week of the radiation therapy.
  • Thereafter, 22 patients received 3-10 cycles of adjuvant chemotherapy with same doses.
  • The toxicity of the treatment was scored according to WHO criteria.
  • All patients underwent nutritional assessment at the time of radiochemotherapy.
  • At the time of the study, 2 patients (6.4%) were surgically proven disease free.
  • Tumor down-staging and resectability rates were high, together with prolonged survival and a good quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989594.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • We herein report on two rare cases of remnant pancreatectomy used to treat recurrent or metachronous pancreatic carcinomas.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant proximal pancreatectomy with duodenectomy was performed and a metachronous pancreatic carcinoma (stage III) was confirmed pathologically.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • FDG-PET can play a key role in detecting remnant pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18. Humans. Male. Neoplasm, Residual

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Bauditz J, Rudolph B, Wermke W: Osteoclast-like giant cell tumors of the pancreas and liver. World J Gastroenterol; 2006 Dec 28;12(48):7878-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-like giant cell tumors of the pancreas and liver.
  • Osteoclast-like giant cell tumors (OGCT) are rare abdominal tumors, which mainly occur in the pancreas.
  • Here we report on two cases of osteoclast-like giant cell tumors, one located within the pancreas, the other within the liver, in which OGCTs are extremely rare.
  • Both patients were investigated by contrast sonography, which demonstrated a complex, partly cystic and strongly vascularized tumor within the head of the pancreas in the first patient and a large, hypervascularized neoplasm with calcifications within the liver in the second patient.
  • With a combination of surgical resection, radiofrequency ablation and chemotherapy, the patient's survival is currently more than 15 mo, making him the longest survivor with an OGCT of the liver to date.
  • [MeSH-major] Giant Cell Tumors / pathology. Liver Neoplasms / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):516-20 [15953882.001]
  • [Cites] Int J Clin Oncol. 2002 Dec;7(6):376-80 [12494256.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):761-6 [15209622.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Cancer. 1977 Mar;39(3):1181-9 [912652.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):771-9 [6994872.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):837-42 [6331629.001]
  • [Cites] Tumori. 1985 Dec 31;71(6):615-20 [3001983.001]
  • [Cites] Acta Pathol Jpn. 1987 Aug;37(8):1327-35 [3673575.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):111-6 [2153001.001]
  • [Cites] Cancer. 1992 May 15;69(10):2444-8 [1314689.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Histopathology. 1993 Aug;23(2):187-9 [8406392.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1055-7 [8281385.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):334-5 [8634058.001]
  • [Cites] Pathol Int. 1997 May;47(5):318-24 [9143028.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):215-8 [9334844.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1247-54 [9777987.001]
  • [Cites] Pancreas. 1999 Apr;18(3):308-15 [10206490.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):207-14 [15694816.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Pancreatology. 2005;5(2-3):279-84 [15849490.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):77-80 [11232955.001]
  • (PMID = 17203538.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087560
  •  go-up   go-down


36. Lee YJ, Jung SH, Hyun WJ, Kim SH, Lee HIe, Yang HW, Kim A, Cha SW: A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis. Gut Liver; 2009 Dec;3(4):338-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis.
  • Abdominal tuberculosis is not a rare disease, but obstructive jaundice caused by tuberculosis (tuberculous lymphadenitis, tuberculous enlargement of the head of pancreas, and/or tuberculous stricture of the biliary tree) is rare.
  • We recently experienced a case of obstructive jaundice as a result of paradoxical reaction of periportal tuberculous lymphadenopathy that was treated successfully with corticosteroid and biliary drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infection. 1997 Jul-Aug;25(4):233-9 [9266263.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):3098-100 [18494068.001]
  • [Cites] Chest. 1998 Sep;114(3):933-6 [9743188.001]
  • [Cites] J Clin Gastroenterol. 1999 Sep;29(2):161-4 [10478878.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2534-6 [10484020.001]
  • [Cites] Clin Microbiol Infect. 2000 Mar;6(3):137-41 [11168089.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9 [12461590.001]
  • [Cites] Surg Today. 2003;33(3):229-31 [12658393.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Oct;22(10):597-602 [14508660.001]
  • [Cites] Thorax. 2004 Aug;59(8):704-7 [15282393.001]
  • [Cites] Am J Gastroenterol. 1989 Apr;84(4):413-4 [2929563.001]
  • [Cites] Q J Med. 1986 Jun;59(230):599-610 [3749451.001]
  • [Cites] Lancet. 1980 Jun 7;1(8180):1208-11 [6104034.001]
  • [Cites] Lancet. 1984 Jul 28;2(8396):181-4 [6146749.001]
  • [Cites] Clin Infect Dis. 1994 Dec;19(6):1092-9 [7888539.001]
  • [Cites] Chest. 1994 Dec;106(6):1896-8 [7988222.001]
  • [Cites] Respir Med. 1996 Apr;90(4):211-4 [8736654.001]
  • [Cites] Am J Gastroenterol. 1996 Dec;91(12):2602-4 [8946995.001]
  • [Cites] Clin Infect Dis. 2005 May 1;40(9):1368-71 [15825042.001]
  • [Cites] Transpl Infect Dis. 2007 Sep;9(3):219-24 [17692068.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):779-81 [17846849.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jul;158(1):157-61 [9655723.001]
  • (PMID = 20431773.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852721
  • [Keywords] NOTNLM ; Abdominal tuberculosis / Paradoxical reaction / Periportal lymphadenitis
  •  go-up   go-down


37. Choi SH, Hwang HK, Kang CM, Lee WJ: Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas. JOP; 2010;11(6):638-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas.
  • CONTEXT: Mucinous cystic tumors occur almost exclusively in middle-aged women and in the body or tail of the pancreas.
  • Mucinous cystadenocarcinoma, a malignant sub-type of mucinous cystic tumors, in the head of the pancreas and in a middle-aged man is extraordinary, and the prognosis and proper management of mucinous cystadenocarcinoma has not been well documented.
  • CASE REPORT: A 52-year-old male patient with a mucinous cystadenocarcinoma approximately 5.5 cm in size in the head of the pancreas underwent a total pancreaticoduodenectomy and segmental resection of the superior mesenteric vein-portal vein confluence with an autologous splenic vein graft due to tumor invasion.
  • His postoperative course was uneventful and he received adjuvant chemotherapy.
  • CONCLUSION: Mucinous cystadenocarcinoma in the head of the pancreas in a middle-aged man is an extremely rare case.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Mesenteric Veins / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Portal Vein / surgery. Splenic Vein / transplantation
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21068503.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


38. Chan WH, Cheow PC, Chung AY, Ong HS, Koong HN, Wong WK: Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results. ANZ J Surg; 2008 Sep;78(9):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results.
  • BACKGROUND: Pancreaticoduodenectomy (PD) for locally advanced stomach cancer involving duodenum or/and pancreatic head was controversial and rarely carried out.
  • METHODS: A review of prospective database from January 2003 to December 2006 of patients who had locally advanced stomach cancer involving duodenum or/and head of pancreas that precluded curative subtotal gastrectomy who underwent diagnostic laparoscopy or exploratory laparotomy to exclude peritoneal metastatic disease.
  • Patients were advised to undergo neoadjuvant chemotherapy before PD.
  • Only four patients had neoadjuvant chemotherapy before PD.
  • The median operative time was 8 h (range 6-9 h).
  • Three patients developed controlled pancreatic leaks and fistulas that were successfully treated with conservative measures.
  • Patients who received neoadjuvant chemotherapy seemed to have better survival rate (P = 0.039).
  • CONCLUSION: Our initial experience has shown that with careful and stringent patients selection, PD for locally advanced stomach cancer can be carried out with acceptable morbidity and mortality.
  • Early results for patients who received neoadjuvant chemotherapy showed trend towards prolonged survival.
  • [MeSH-major] Duodenal Neoplasms / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Feasibility Studies. Humans. Neoplasm Invasiveness. Treatment Outcome


39. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, Levy P, Ruszniewski P: Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol; 2006 Apr;101(4):735-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.
  • BACKGROUND: Life expectancy in patients with unresectable pancreatic cancer has improved by using new chemotherapeutic regimens.
  • AIM: To evaluate the incidence of biliary and duodenal stenoses as well as technical success and short- and long-term patency of endoscopically deployed stents in patients with unresectable pancreatic cancer.
  • PATIENTS AND METHODS: All consecutive patients with unresectable cancer of the pancreatic head seen between January 1999 and September 2003 in our center were retrospectively studied.
  • Patients with biliary and/or duodenal stenoses underwent endoscopic stent insertion as first intention therapy.
  • RESULTS: One hundred patients, median age 65 yr (32-85), with locally advanced (62%) or metastatic (38%) pancreatic cancer were studied.
  • Eighty-three percent received at least one line of chemotherapy.
  • In the 23 patients who developed both biliary and duodenal stenoses, combined stenting was successful in 91% of cases.
  • No major complication or death occurred related to endoscopic treatment.
  • CONCLUSION: Endoscopic palliative treatment of both biliary and duodenal stenoses is safe and effective in the long term, including in patients with combined obstructions.
  • [MeSH-major] Adenocarcinoma / complications. Biliary Tract. Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Duodenum. Palliative Care. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / therapy. Endoscopy. Female. Humans. Male. Middle Aged. Survival Rate


40. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • Three courses of intra-arterial infusion of mitomycin C and microspheres (1000 mg) resulted in regression of her tumor and a decrease of tumor marker levels.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • As her metastases were controlled for about 7 months, hepatic arterial infusion of mitomycin C and degradable starch microspheres appears to be useful for treating liver metastasis of pancreatic cancer, but careful attention should be paid to the risk of severe complications such as bile duct necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


41. Kalil AN, Reck dos Santos PA, Azambuja DB, Beck PE: A case of retroperitoneal lymphoma presenting as pancreatic tumor. Hepatogastroenterology; 2004 Jan-Feb;51(55):259-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of retroperitoneal lymphoma presenting as pancreatic tumor.
  • We describe a case of non-Hodgkin's lymphoma arising in the peripancreatic retroperitoneal lymph node and extending into the pancreatic parenchyma.
  • Abdominal ultrasonogram and computed tomography of the abdomen showed an mass in the head of pancreas with absence of extrapancreatic disease and no direct tumor extension to the portal vein or superior mesenteric artery.
  • Laparotomy demonstrated a large pancreatic mass with no obstruction of common bile duct or encasement of portal vein and superior mesenteric artery and a pancreaticoduodenectomy was performed.
  • He received chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone.
  • The patient is alive and in remission with a follow-up time of 24 months.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011880.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


42. Défachelles AS, Martin De Lassalle E, Boutard P, Nelken B, Schneider P, Patte C: Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients. Med Pediatr Oncol; 2001 Jul;37(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients.
  • BACKGROUND: To analyze the clinical course of pancreatoblastoma in children and to propose management and therapy.
  • PROCEDURE: Retrospective review of seven cases of pancreatoblastoma treated in France over a 20-year period and literature review.
  • The tumor was well encapsulated in one patient and had direct extension to adjacent tissues in two others.
  • The tumor arose in the head of the pancreas in three children, in the tail and body in two and in the tail and in the body, one each.
  • Five tumor resections were performed, one initially and 4 after neoadjuvant chemotherapy, and cisplatin plus doxorubicin seemed effective.
  • In all, four children are disease free with a median follow-up of 50 months ( range, 5--120 months) : one had a complete removal of tumor at diagnosis and no further treatment, three had unresectable tumor at diagnosis and received neoadjuvant chemotherapy with cisplatin and doxorubicin.
  • CONCLUSIONS: Pancreatoblastoma is a curable tumor.
  • Examination of serum AFP levels may be useful for diagnosis and to follow the course of the disease.
  • Complete resection is the treatment of choice.
  • However, tumor is often unresectable at diagnosis and preoperative chemotherapy is needed to reduce tumor volume.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Retrospective Studies. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11466723.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 48
  •  go-up   go-down


43. Lin H, Li SD, Hu XG, Li ZS: Primary pancreatic lymphoma: report of six cases. World J Gastroenterol; 2006 Aug 21;12(31):5064-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma: report of six cases.
  • AIM: To heighten recognition of primary pancreatic lymphoma (PPL) in clinical practice.
  • METHODS: A retrospective review of the clinical presentation, imaging characteristics and pathological features of PPL patients were presented, as well as their diagnosis and treatment, in combination with literature review.
  • RESULTS: Histological diagnosis was made in four patients by surgery and in two patients by EUS-FNA.
  • One of the patients developed acute pancreatitis.
  • Abdominal CT scan showed that three of the six tumors were located in the head of pancreas, two in the body and tail, and one throughout the pancreas.
  • Diameter of the tumors in the pancreas in four cases was more than 6 cm, with homogeneous density and unclear borders.
  • Enhanced CT scan showed that only the tumor edges were slightly enhanced.
  • The pancreatic duct was irregularly narrowed in two cases whose tumors were located in the pancreatic head and body, in which endoscopic retrograde cholangiopancreatography (ERCP) showed that the proximal segment was slightly dilated.
  • The diagnosis of B-cell non-Hodgkin's lymphoma was made in all patients histopathologically.
  • All six patients underwent systemic chemotherapy, one of whom was also treated with gamma radiometry.
  • One patient died two weeks after diagnosis, two patients lost follow-up, two patients who received chemotherapy survived 49 and 37 mo, and the remaining patient is still alive 21 mo, after diagnosis and treatment.
  • CONCLUSION: PPL is a rare form of extranodal lymphoma originating from the pancreatic parenchyma.
  • Clinical and imaging findings are otherwise not specific in the differentiation of pancreatic lymphoma and pancreatic cancer, which deserves attention.
  • EUS-guided fine-needle aspiration (EUS-FNA) of the pancreas requires experienced cytopathologists as well as advanced immunohistochemical assays to obtain a final diagnosis on a small amount of tissue.
  • Surgery and adjuvant chemotherapy or radiotherapy can produce fairly good outcomes.
  • [MeSH-major] Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):671-5 [10701607.001]
  • [Cites] JOP. 2006;7(3):262-73 [16685107.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):485-91 [11275890.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Surg Endosc. 2002 Jul;16(7):1107-8 [11984658.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):898-903 [15198364.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Am J Surg. 1979 Dec;138(6):929-33 [92204.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Am Surg. 1993 Aug;59(8):513-8 [8338282.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] Eur Radiol. 1997;7(6):875-86 [9228103.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Surgery. 1998 Apr;123(4):382-90 [9551063.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):80-2 [9577380.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1329-33 [9707060.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] Haematologica. 2005 Feb;90(2):ECR09 [15713583.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • (PMID = 16937508.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087415
  •  go-up   go-down


44. Sugimoto K, Okada K, Nakahira S, Okamura S, Miki H, Nakata K, Suzuki R, Yoshimura M, Uji K, Yoshida A, Tamura S: [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine]. Gan To Kagaku Ryoho; 2009 Feb;36(2):321-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
  • We report a case of pancreas head cancer with liver metastasis treated with uracil-tegafur (UFT) and gemcitabine combined chemotherapy.
  • The histopathological diagnosis was adenocarcinoma, so we inserted a self-expandable metallic stent (EMS) in this inoperable pancreas head cancer.
  • We performed 9 courses of UFT and gemcitabine (GEM) combination chemotherapy.
  • Renewed liver metastases did not appear, and the pancreas head tumor partially responded.
  • After treatment with an additional 11 courses of chemotherapy, he took S-1 orally because of a tumor recurrence.
  • Combination chemotherapy and surgery enhanced the survival benefit in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Tomography, X-Ray Computed


45. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • The patient, a 63-year-old man had a large tumor in the head of the pancreas, without obstructive jaundice.
  • Invasion of the tumor into the duodenum and transverse colon induced progressive anemia and ileus.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Nakagawa Y, Todoroki T, Morishita Y, Mori K, Nakahaashi C, Ohkohchi N, Matsumoto H: A long-term survivor after pancreaticoduodenectomy for metastatic undifferentiated carcinoma of an unknown primary. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With this context, there is no report of a long-term (> 5-year) disease-free survivor after a pancreaticoduodenectomy (PD).
  • A 53-year-old female had complaints of intermittent high fever and a large palpable epigastric tumor.
  • A CT scan revealed that a very large well-circumscribed solid mass occupied the posterior portion of the head of the pancreas and extended to the hepatic hilum.
  • The serum carcinoembryonic antigen (CEA), CA-125 and carbohydrate antigen 19-9 (CA19-9) levels were within the normal ranges.
  • Histologically, the tumor showed solid or diffuse proliferation of pleomorphic cells, and the immunohistochemistry suggested a metastatic tumor originating from the epithelium, the primary site was not determined despite of full review of all metastatic lesions to pancreas handled surgically and non-surgically.
  • Adjuvant oral chemotherapy of UFT and cimetidine continued for 3 years and the patient alive and healthy 6 years after surgery.
  • Even for dismal prognostic undifferentiated CUP, radical surgery would be an effective component of multidisciplinary treatment, provided that the tumor is respectable without elevation of serum tumor markers and adjuvant chemotherapy is able to appropriately supplement.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Survivors. Tegafur / therapeutic use. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102342.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


47. Minchom A, Chan S, Melia W, Shah R: An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer; 2010 Jun;41(2):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of pancreatic cancer with leptomeningeal infiltration.
  • INTRODUCTION: Pancreatic cancer is a common malignancy and often presents at an advanced stage.
  • We aim to describe an unusual case of leptomeningeal involvement from pancreatic cancer.
  • CASE REPORT: A 59-year-old man presented with a several-year history of abdominal pain, weight loss and anaemia, which had been extensively investigated.
  • CT scan of the abdomen showed subtle narrowing of the common bile duct and pancreatic ducts.
  • Endoscopic ultrasound showed a 5-cm lesion in the head of the pancreas with adenocarcinoma cells on fine needle aspiration.
  • He started on a weekly regimen of intrathecal combination chemotherapy of hydrocortisone 50 mg, methotrexate 12.5 mg and cytarabine 50 mg.
  • His clinical condition continued to deteriorate, cytotoxic therapy was withdrawn after 2 weeks and he died the following month.
  • DISCUSSION: This case represents the unusual presentation of advanced leptomeningeal carcinomatosis in a locally early stage pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Carcinomatosis / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Humans. Hydrocortisone / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2006 Mar 14;66(5):783; author reply 783 [16534138.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • [Cites] Neurochirurgia (Stuttg). 1980 Jan;23(1):13-7 [7352044.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Dec;35(13):2413-6 [19098414.001]
  • [Cites] Acta Neurol (Napoli). 1975 Jul-Aug;30(4):359-67 [1229842.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5 [10917346.001]
  • [Cites] Cancer Treat Res. 2005;125:147-58 [16211888.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 20069465.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


48. Pietsch JB, Shankar S, Ford C, Johnson JE: Obstructive jaundice secondary to lymphoma in childhood. J Pediatr Surg; 2001 Dec;36(12):1792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports in adults and children suggest that these lymphomas are associated with a poor prognosis.
  • Abdominal ultrasound scan and computed tomography (CT) scans were helpful in defining the anatomy of the obstruction.
  • In the cases of involvement of the porta hepatis, the diagnosis was made by biopsy.
  • In one child a mass was in the head of the pancreas, and evaluation of frozen section biopsy results were not diagnostic for lymphoma, and a major resection was performed.
  • All the lymphomas were of nonHodgkin's B-cell type and one was a Burkitt's lymphoma.
  • All responded promptly to chemotherapy.
  • One child had a testicular relapse and currently is receiving additional therapy.
  • Biopsy alone without resection or biliary drainage is recommended surgical therapy.
  • Long-term survival rate in children with this disorder appears to be more promising than previously reported.
  • [MeSH-major] Cholestasis / etiology. Lymphoma / complications. Pancreatic Neoplasms / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Female. Humans. Male. Prognosis. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11733908.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Miura T, Endo Y, Matumoto Y, Ikeda H: [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival]. Gan To Kagaku Ryoho; 2000 Oct;27(12):1794-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
  • Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented.
  • A patient with cancer in the pancreatic head with accompanying extensive metastasis in both hepatic lobes was treated by sub selective aortic infusion of 5-FU and MMC with microwave hyperthermia.
  • Both the cancer in the pancreatic head and the liver metastasis showed complete remission for 16 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Liver Neoplasms / secondary. Microwaves / therapeutic use. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Remission Induction. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11086415.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Hisama S, Kimura M, Nishimura T, Matsushita H, Okamura S, Saitoh S, Shimokawa Y, Arakawa A, Toyama H, Tanaka Y: [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1337-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
  • A 65-year-old man suffering from acute pancreatitis underwent MRI scanning, which revealed a low signal on the T1 and T2 sequences, and hypovascularity in arterial phase in the head of the pancreas.
  • FDG-PET was highly suggestive of pancreatic cancer (T4N1M0, Stage IVa) with lymph node metastasis.
  • He was treated with systemic chemotherapy using gemcitabine (GEM) followed by radiotherapy.
  • His symptoms gradually improved with a reduction in size of the primary lesion.
  • The patient has been receiving systemic chemotherapy using S-1 without recurrence.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Remission Induction. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


51. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinoma of the stomach is an uncommon tumor, usually associated with highly malignant biological behavior and extremely poor prognosis.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • During the operation, an obviously swollen lymph node on the anterior surface of the head of the pancreas 4.0 x 3.5 cm in size was found growing into the parenchyma of the pancreas head and could not be separated from the pancreas, and the swollen lymph node along the superior mesenteric vein was also hard and suspected to be a metastatic node.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor to be neuroendocrine carcinoma.
  • The obvious swollen lymph node on the anterior surface of the head of the pancreas and the swollen lymph node along the superior mesenteric vein were also identified as metastatic lymph nodes.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


52. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • CT is the most important way of diagnosis and the combination of B-ultrasound, CT and MRI may improve the rate of diagnosis up to 96.6%.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer; 2009 Feb 25;9:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.
  • BACKGROUND: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage.
  • However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome.
  • This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I(131) in pancreatic cancer (ISRCTN 16857581).
  • METHODS: Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route.
  • One patient was still alive at the time of this analysis.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoembryonic Antigen / administration & dosage. Immunotoxins / administration & dosage. Iodine Radioisotopes / administration & dosage. Pancreatic Neoplasms / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Neoplasm / biosynthesis. Antibodies, Neoplasm / immunology. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Middle Aged. Radiography. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s [10541369.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):406-14 [10690517.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):45-57 [11135320.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6851-9 [11559561.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1373-81 [11877768.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Clin Colorectal Cancer. 2002 May;2(1):31-42 [12453334.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69 [14653825.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):618-26 [14991585.001]
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):11-22 [794493.001]
  • [Cites] Ann N Y Acad Sci. 1983;417:75-85 [6200051.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] J Surg Oncol. 1991 Jul;47(3):148-54 [2072697.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):858-70 [9189130.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):34-42 [9443735.001]
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9 [9756018.001]
  • [Cites] Hybridoma. 1999 Apr;18(2):183-91 [10380018.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Ann Nucl Med. 2005 Jul;19(5):355-65 [16164191.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):196-9 [16455623.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):247-55 [16455630.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):823-34 [16380412.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Curr Drug Discov Technol. 2006 Dec;3(4):231-43 [17430101.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 19243606.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN16857581
  • [Grant] United Kingdom / Medical Research Council / / G9900432; United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2656541
  •  go-up   go-down


54. Faraj W, Jamali F, Khalifeh M, Hashash J, Akel S: Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature. Eur J Pediatr Surg; 2006 Oct;16(5):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature.
  • Solid pseudopapillary neoplasms of the pancreas (SPNP) are rare pancreatic tumors that occur predominantly in young women, with very few cases reported in men.
  • While the origin of the tumor may be unclear, it is characterized by a distinct histological appearance and a clinical course highlighting its low malignant potential.
  • The role of chemotherapy and radiation therapy in the management of SPNP is still controversial.
  • We report here on an unusual occurrence of SPNP in the area of the head of the pancreas in a 12-year-old female treated by pancreatico-duodenectomy, together with a review of the literature.
  • [MeSH-major] Pancreatic Neoplasms / surgery
  • [MeSH-minor] Child. Female. Humans. Pancreaticoduodenectomy. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160784.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


55. Lall DG, Karanjia ND, Giddings AE: Regional pancreatectomy and transverse colectomy with mesenteric vascular reconstruction for inflammatory pseudotumour of the head of pancreas and mesenteric root. HPB (Oxford); 2002;4(4):179-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional pancreatectomy and transverse colectomy with mesenteric vascular reconstruction for inflammatory pseudotumour of the head of pancreas and mesenteric root.
  • BACKGROUND: Inflammatory myofibroblastic pseudotumour is a rare pancreatic lesion.
  • CASE OUTLINE: A 32-year-old woman with such a tumour was treated by a radical operation comprising proximal pancreatic-duodenectomy (Whipple Procedure) and transverse colectomy with resection and reconstruction of the superior mesenteric artery and vein.
  • DISCUSSION: The importance of aggressive surgical clearance rather than chemotherapy is highlighted in the management of patients with these unusual tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1992 Dec;79(12):1357-60 [1486440.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):102-10 [9606802.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1247-51 [7475715.001]
  • (PMID = 18332951.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020548
  •  go-up   go-down


56. Hsu JT, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, Chen MF: Adenosquamous carcinoma of the pancreas. Digestion; 2005;72(2-3):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas.
  • BACKGROUND/AIMS: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult.
  • Case reports of ASC of the pancreas are sporadic and have typically employed small series.
  • This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease.
  • METHODOLOGY: Seven patients (4 men and 3 women; age range 38-79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed.
  • The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2.
  • Three patients received postoperative adjuvant chemotherapy.
  • CONCLUSIONS: Patients with ASC present symptoms similar to those of adenocarcinoma of the pancreas.
  • Most patients had dismal prognosis despite aggressive surgery with or without adjuvant therapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16172546.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Albu A, Zirnea A, Georgescu O, Terzea D, Jinga D, Fica S: Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature. J Med Life; 2008 Apr-Jun;1(2):210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature.
  • Malignant insulinomas are rare tumors (10% of insulinomas) that often present as mnulticentric macro nodules with multiple liver metastases before diagnosis.
  • We report the case of a 55 year old female with a medical history of severe hypoglycemic attacks for two months.
  • Blood tests showed a decreased value of glycemia (30 mg/dl) associated with increased insulin level (l6 microU/ml) and an increased glycemia/insulinemia ratio of 1.87 supporting the diagnosis of insulinoma.
  • Abdominal CT showed a 1.5 cm mass localized in the head of the pancreas with disseminated hepatic tumors, confirmed as neuroendocrine metastases by biopsy (which proved the presence of a malignant insulinoma).
  • Primary hyperparathyroidism was diagnosed based on mild elevation of calcium (10.4 mg/dl) associated with a high level of PTH (71.2 pg/ml).
  • The coexistence of the two endocrinopathies suggested the presence of type 1 multiple endocrine neoplasia (MEN 1).
  • Somatostatin analog therapy was started with symptomatic control in the beginning, but rapid loss of beneficial effect.
  • Finally, systemic chemotherapy with doxorubicin was administered, but the disease was progressive and after three months we decided to stop it.
  • [MeSH-major] Hyperparathyroidism, Primary / complications. Insulinoma / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology


58. Chang YT, Chang MC, Wong JM: Education and imaging. Hepatobiliary and pancreatic: duplication of the main pancreatic duct in the head of pancreas. J Gastroenterol Hepatol; 2008 Feb;23(2):337
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education and imaging. Hepatobiliary and pancreatic: duplication of the main pancreatic duct in the head of pancreas.
  • [MeSH-major] Pancreas / abnormalities. Pancreas / radiography. Pancreatic Ducts / abnormalities. Pancreatic Ducts / radiography
  • [MeSH-minor] Adult. Cholangiopancreatography, Endoscopic Retrograde. Female. Gastroenterology / education. Humans. Pancreatitis / drug therapy. Pancreatitis / etiology. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289362.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


59. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg; 2001 Mar-Apr;5(2):121-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.
  • We examined the effect of preoperative chemoradiotherapy on the ability to obtain pathologically negative resection margins in patients undergoing pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas.
  • Between 1987 and 2000, 100 patients underwent Whipple resection with curative intent for primary adenocarcinoma of the head of the pancreas.
  • Pathologic assessment of six margins (proximal and distal superior mesenteric artery, proximal and distal superior mesenteric vein, pancreas, retroperitoneum, common bile duct, and hepatic artery) was undertaken by either frozen section (pancreas and common duct) or permanent section.
  • A margin was considered positive if tumor was present less than 1 mm from the inked specimen.
  • Of the 100 patients treated, 47 (47%) underwent postoperative radiation and chemotherapy (group I) and 53 (53%) received preoperative chemoradiotherapy (group II) with either 5-fluorouracil (32 patients) or gemcitabine (21 patients).
  • Patient demographics and operative parameters were similar in the two groups, with the exception of preoperative tumor size (CT scan), which was greater in group II (P < 0.001), and number of previous operations, which was greater in group II (P < 0.0001).
  • Statistical analysis of the number of negative surgical margins clear of tumor was performed using Fisher's exact test.
  • All patients (100%) had six margins assessed for microscopic involvement with tumor.
  • In the preoperative therapy group, 5 (7.5%) of 53 patients had more than one positive margin, whereas 21 (44.7%) of 47 patients without preoperative therapy had more than one margin with disease extension (P < 0.001).
  • Additionally, only 11 (25.6%) of the 47 patients without preoperative therapy had six negative margins vs. 27 (50.9%) of 53 in the group receiving preoperative therapy (P = 0.013).
  • Similarly, a strong trend toward improved disease-free and overall survival is seen in patients with a single positive margin vs. multiple margins.
  • However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Sep;206(3):366-73 [2820322.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):79-84 [3121546.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):65-71 [3015059.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Cancer. 1976 Mar;37(3):1519-24 [1260670.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):227-32 [7799024.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):96-101 [1509287.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):117-22 [10030424.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • (PMID = 11331473.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT: Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol; 2010;5:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.
  • PURPOSE: To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma.
  • Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%).
  • The majority of patients (83%) had IORT at the time of their definitive surgery.
  • Additional mean clinical characteristics include: age 64 (range 41-81); tumor size 4 cm (range 1.4-11); and IORT dose 1106 cGy (range 600-1500).
  • Post-operative external beam radiation (EBRT) or chemotherapy was given to 65% and 76% of the assessable patients, respectively.
  • Outcomes measured were infield control (IFC), loco-regional control (LRC), distant metastasis free survival (DMFS), overall survival (OS) and treatment-related complications.
  • Our cohort had three grade 3-5 complications associated with treatment (surgery and IORT).
  • CONCLUSIONS: Orthovoltage IORT following tumor reductive surgery is reasonably well tolerated and seems to confer in-field control in carefully selected patients.
  • However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • (PMID = 21059255.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987939
  •  go-up   go-down


61. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country.
  • Risk factors include smoking, certain familial cancer syndromes, and familial chronic pancreatitis.
  • The link between risk of pancreatic cancer and other factors (e.g., diabetes, obesity) is less clear.
  • Most patients present with obstructive jaundice caused by compression of the bile duct in the head of the pancreas.
  • Epigastric or back pain, vague abdominal symptoms, and weight loss also are characteristic of pancreatic cancer.
  • More than one half of cases have distant metastasis at diagnosis.
  • Computed tomography is the most useful diagnostic and staging tool.
  • The majority of tumors are not surgically resectable because of metastasis and invasion of the major vessels posterior to the pancreas.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Adjuvant fluorouracil-based chemotherapy may prolong survival.
  • For nonresectable tumors, chemotherapy with gemcitabine prolongs survival.
  • Radiation combined with chemotherapy has slowed progression in locally advanced cancers.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


62. Ohata R, Okazaki T, Ishizaki Y, Fujimura J, Shimizu T, Lane GJ, Yamataka A, Kawasaki S: Pancreaticoduodenectomy for pancreatoblastoma: a case report and literature review. Pediatr Surg Int; 2010 Apr;26(4):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging studies showed a solid 4 cm tumor in the head of the pancreas and two lesions in the liver.
  • After five courses of chemotherapy, the primary tumor was completely resected with pancreaticoduodenectomy (PD) and Child's pancreaticobiliary tract reconstruction.
  • [MeSH-major] Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Biopsy, Needle. Child. Follow-Up Studies. Humans. Male. Pancreas / surgery. Rare Diseases. Reconstructive Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2010 May;54(5):675-80 [19998473.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Pediatr Radiol. 2004 Jul;34(7):583 [15205844.001]
  • [Cites] J Pediatr Surg. 2006 Mar;41(3):596-8 [16516645.001]
  • [Cites] Lahey Clin Bull. 1955 Jul;9(5):155-9 [13252875.001]
  • [Cites] J Pediatr Surg. 1992 Oct;27(10):1315-7 [1328584.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):319-27 [6307069.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1734-6 [3115557.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] Histopathology. 1980 Jan;4(1):87-104 [6965487.001]
  • [Cites] Pancreatology. 2004;4(5):441-51; discussion 452-3 [15256806.001]
  • [Cites] Cancer. 1976 Mar;37(3):1508-18 [1260669.001]
  • [Cites] Surgery. 1984 Apr;95(4):420-6 [6710338.001]
  • [Cites] Diagn Cytopathol. 2001 Aug;25(2):118-21 [11477717.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):963-9 [6141001.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):201-5 [3048135.001]
  • [Cites] Acta Pathol Jpn. 1983 May;33(3):565-75 [6353853.001]
  • [Cites] Cancer. 1977 Jan;39(1):247-54 [188539.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6(6):369-72 [9007475.001]
  • [Cites] Arch Surg. 1970 Sep;101(3):370-5 [4194202.001]
  • [Cites] Am J Dis Child. 1974 Jul;128(1):101-4 [4834991.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Dec;29(12 ):845-7 [18090935.001]
  • [Cites] World J Surg. 1998 Aug;22(8):879-82 [9673563.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Ann Surg. 1957 Jun;145(6):864-70; discussions, 870-2 [13425296.001]
  • [Cites] Pancreas. 2007 Jan;34(1):92-5 [17198189.001]
  • [Cites] J Pediatr Surg. 2009 Jan;44(1):197-203 [19159743.001]
  • [Cites] World J Surg. 1986 Oct;10(5):851-9 [3022489.001]
  • [Cites] Med Pediatr Oncol. 1997 Sep;29(3):237 [9212854.001]
  • (PMID = 20165952.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  •  go-up   go-down


63. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg; 2007 Nov;11(11):1460-7; discussion 1467-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.
  • The natural history of pancreatic neuroendocrine tumors (PNET) remains poorly defined.
  • Our objectives were to examine the clinicopathologic features of PNETs, to assess treatment trends over time, and to identify factors associated with undergoing resection.
  • From the National Cancer Data Base (1985-2004), 9,821 patients were identified with PNETs.
  • Clinicopathologic features and treatment trends were examined.
  • Of the 3,851 (39.0%) patients who underwent pancreatectomy, 449 (11.7%) received adjuvant chemotherapy, and 254 (6.6%) received adjuvant radiation.
  • Patients were less likely to undergo resection if they were > 55 years old, had tumors in the head of the pancreas, tumors > or = 4 cm, or had distant metastases (P < 0.0001).
  • As PNETs have a better prognosis than adenocarcinoma, concerns regarding the morbidity and mortality of pancreatic surgery and neoplasms should not preclude resection.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jan 15;65(2):354-7 [2153046.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Ann Intern Med. 1949 Oct;31(4):624-7 [15390535.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] World J Surg. 2007 Mar;31(3):579-85 [17219270.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1806-10 [16085691.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):327-31 [16504877.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1806-9 [15188511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73 [16030115.001]
  • [Cites] ANZ J Surg. 2001 Aug;71(8):475-82 [11504292.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):962-9 [15525824.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Dig Surg. 2005;22(3):157-62 [16043962.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):469-72 [15313691.001]
  • [Cites] J Surg Oncol. 2004 Jan;85(1):1-3 [14696080.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 17846854.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G: Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain. Onkologie; 2009 Mar;32(3):119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Only few cases of pancreatic involvement of multiple myeloma (MM) have been reported in the medical literature.
  • PATIENTS AND METHODS: We here report a case of devastating extramedullary relapse of IgA/lambdaMM (stage IA) treated at diagnosis with a dexamethasone, adriamycin, vincristine (DAV) regimen followed by high-dose therapy and autologous stem cell transplantation (ASCT), achieving a partial remission.
  • After 6 years of stable disease, the patient presented symptoms of obstructive jaundice determined by a large mass of the head of the pancreas.
  • An ultrasound-guided fine-needle aspiration cytology of the pancreatic mass revealed the presence of myeloma plasma cells.
  • RESULTS: We observed a progression of disease despite an aggressive treatment with high-dose cyclophosphamide.
  • CONCLUSIONS: Our case shows that extramedullary relapses of MM after ASCT are very resistant to conventional chemotherapy.
  • The role of new drugs and the optimal treatment strategy in these cases remain to be defined.
  • [MeSH-major] Abdominal Pain / prevention & control. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Immunoglobulin lambda-Chains / analysis. Jaundice, Obstructive / prevention & control. Multiple Myeloma / drug therapy. Neoplasm Recurrence, Local / prevention & control. Pancreatic Neoplasms / drug therapy


65. Demirkan B, Unek IT, Eriksson B, Akarsu M, Durak H, Sağol O, Obuz F, Binicier C, Füzün M, Alakavuklar M: A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report. Turk J Gastroenterol; 2009 Sep;20(3):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
  • Pancreatic neuroendocrine tumors constitute about 2% of all gastrointestinal neoplasms.
  • Approximately half of the pancreatic euroendocrine tumors are nonfunctional.
  • Due to lack of specific symptoms, most patients with nonfunctional pancreatic neuroendocrine tumors present with locally advanced or metastatic disease.
  • Colon carcinoma ranks third in frequency among primary sites of cancer in both men and women in western countries.
  • Presence of a metachronous colon adenocarcinoma in a patient with nonfunctional pancreatic neuroendocrine tumor has not been reported before.
  • We present a patient who had an asymptomatic mass in the head of the pancreas, detected by ultrasonography in 1996.
  • In 2002, after the diagnosis of an unresectable, nonfunctional pancreatic neuroendocrine tumor, interferon alpha- 2b and octreotide were started.
  • A year after biological treatment, he refused further treatment.
  • In 2004, during the evaluation of dissemination of the asymptomatic disease, positron emission tomography revealed a high uptake by the descending colon despite the failure of other imaging methods.
  • After surgery for operable colon carcinoma, the patient received chemotherapy and biological therapy for both tumors.
  • Since 2005, he has been doing well without any further treatment thus far.
  • In conclusion, computerized tomography/magnetic resonance imaging and octreotide scintigraphy may be insufficient to show disseminated disease and asymptomatic second primary malignancies.
  • Therefore, positron emission tomography is a valuable promising option for the evaluation of gastroenteropancreatic neuroendocrine tumors and concomitant or metachronous malignancies.
  • Lifelong follow-up by a multidisciplinary oncology team is needed so that a long-term survival can be achieved with integrated multimodal systemic treatment approaches.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821205.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


66. Nimura Y: [Treatment of pancreatic cancer--surgical point of view]. Gan To Kagaku Ryoho; 2007 Jul;34(7):993-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pancreatic cancer--surgical point of view].
  • Although surgical techniques for pancreatic cancer have developed in a high level, the treatment results have not been improved and the 5 year survival rates after curative operation has been about 15% in Japan.
  • Retrospective studies on extended lymphadenectomy for ductal adenocarcinoma of the head of the pancreas revealed that extended surgery prolonged the survival for resected patients.
  • Finally, the clinical advantages of extended lymphadenectomy for pancreatic cancer was denied by several RCTs from Italy and U.S.A.
  • Although usefulness of radio/chemotherapy has been controversial, adjuvant chemotherapy with gemcitabin significantly prolonged the patients' survival after curative pancreatectomy.
  • Further development of multidisciplinary treatments for pancreatic cancer is expected.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Lymph Node Excision / methods. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637533.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 24
  •  go-up   go-down






Advertisement